Stable expression of chimeric anti-CD3 receptors on mammalian cells for stimulation of antitumor immunity

Cancer Gene Therapy

Volumn 10, Issue 10, 2003, Pages 779-790

  Liao, Kuang Wen ^a   Chen, Bing Mae ^a   Liu, Tang Bi ^a   Tzou, Shey Cherng ^a   Lin, Ya Min ^b   Lin, Kai Feng ^a   Su, Chien I ^a,c   Roffler, Steve R ^a  

^a INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^b INSTITUTE OF MOLECULAR BIOLOGY   (Taiwan)

^c NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

CD3; CD80; CD86; Immunotherapy; Single chain antibodies; T lymphocytes

Indexed keywords

B7 ANTIGEN; CD3 RECEPTOR ANTIBODY; CD86 ANTIGEN; INTERLEUKIN 2; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; ANTIBODIES; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD80; ANTIGENS, CD86; CELL DIVISION; CELL LINE; DISEASE PROGRESSION; GENE THERAPY; HUMANS; IMMUNOTHERAPY; INTERLEUKIN-2; LYMPHOCYTE ACTIVATION; MEMBRANE GLYCOPROTEINS; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECOMBINANT FUSION PROTEINS; SURVIVAL RATE; T-LYMPHOCYTES;

ANIMALIA; MAMMALIA;

EID: 0141885143     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700637     Document Type: Article

References (57)

1. Abken H, Hombach A, Heuser C, et al. Tuning tumor-specific T-cell activation: a matter of costimulation? Trends Immunol. 2002;23:240-245.
2. McHugh RS, Ahmed SN, Wang YC, et al. Construction, purification, and functional incorporation on tumor cells of glycolipid-anchored human B7-1 (CD80). Proc Natl Acad Sci USA. 1995;92:8059-8063.
3. Freeman GJ, Borriello F, Hodes RJ, et al. Murine B7-2, an alternative CTLA4 counter-receptor that costimulates T cell proliferation and interleukin 2 production. J Exp Med. 1993;178:2185-2192.
4. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Ann Rev Immunol. 1996;14:233-258.
5. Hayakawa M, Kawaguchi S, Ishii S, et al. B7-1-transfected tumor vaccine counteracts chemotherapy-induced immunosuppression and prolongs the survival of rats bearing highly metastatic osteosarcoma cells. Int J Cancer. 1997;71:1091-1102.
6. Martin BK, Frelinger JG, Ting JP. Combination gene therapy with CD86 and the MHC class II transactivator in the control of lung tumor growth. J Immunol. 1999;162:6663-6670.
7. Fujii H, Inobe M, Kimura F, et al. Vaccination of tumor cells transfected with the B7-1 (CD80) gene induces the antimetastatic effect and tumor immunity in mice. Int J Cancer. 1996;66:219-224.
8. Korkolopoulou P, Kaklamanis L, Pezzella F, et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer. 1996;73:148-153.
9. Luboldt HJ, Kubens BS, Rubben H, et al. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res. 1996;56:826-830.
10. Kaklamanis L, Townsend A, Doussis Anagnostopoulou IA, et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol. 1994;145:505-509.
11. Vitale M, Rezzani R, Rodella L, et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res. 1998;58:737-742.
12. Restifo NP, Marincola FM, Kawakami Y, et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst. 1996;88:100-108.
13. Paul DB, Barth RF, Yang W, et al. B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity. Gene Therapy. 2000;7:993-999.
14. Chen L, McGowan P, Ashe S, et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med. 1994;179:523-532.
15. Liao KW, Lo YC, Roffler SR. Activation of lymphocytes by anti-CD3 single-chain antibody dimers expressed on the plasma membrane of tumor cells. Gene Therapy. 2000;7:339-347.
16. Paul S, Regulier E, Poitevin Y, et al. The combination of a chemokine, cytokine and TCR-based T cell stimulus for effective gene therapy of cancer. Cancer Immunol Immunother. 2002;51:645-654.
17. Paul S, Regulier E, Rooke R, et al. Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies. Cancer Gene Ther. 2002;9:470-477.
18. Liao KW, Chou WC, Lo YC, et al. Design of transgenes for efficient expression of active chimeric proteins on mammalian cells. Biotechnol Bioeng. 2001;73:313-323.
19. Chou WC, Liao KW, Lo YC, et al. Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotechnol Bioeng. 1999;65:160-169.
20. Groh V, Wu J, Yee C, et al. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419:734-738.
21. Reddy P, Caras I, Krieger M. Effects of O-linked glycosylation on the cell surface expression and stability of decay-accelerating factor, a glycophospholipid-anchored membrane protein. J Biol Chem. 1989;264:17329-17336.
22. Ludwig A, Ehlert JE, Flad HD, et al. Identification of distinct surface-expressed and intracellular CXC-chemokine receptor 2 glycoforms in neutrophils: N-glycosylation is essential for maintenance of receptor surface expression. J Immunol. 2000;165:1044-1052.
23. Workman P, Twentyman P, Balkwill F, et al. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). Br J Cancer. 1998;77:1-10.
24. de Ines C, Cochlovius B, Schmidt S, et al. Apoptosis of a human melanoma cell line specifically induced by membrane-bound single-chain antibodies. J Immunol. 1999;163:3948-3956.
25. Winberg G, Grosmaire LS, Klussman K, et al. Surface expression of CD28 single chain Fv for costimulation by tumor cells. Immunol Rev. 1996;153:209-223.
26. Ye Z, Hellstrom I, Hayden-Ledbetter M, et al. Gene therapy for cancer using single-chain Fv fragments specific for 4-1BB. Nat Med. 2002;8:343-348.
27. Hwang KW, Sweatt WB, Brown IE, et al. Cutting edge: targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 2002;169:633-637.
28. Graf MR, Jadus MR, Hiserodt JC, et al. Development of systemic immunity to glioblastoma multiforme using tumor cells genetically engineered to express the membrane-associated isoform of macrophage colony-stimulating factor. J Immunol. 1999;163:5544-5551.
29. Nagarajan S, Selvaraj P. Glycolipid-anchored IL-12 expressed on tumor cell surface induces antitumor immune response. Cancer Res. 2002;62:2869-2874.
30. Marais R, Spooner RA, Stribbling SM, et al. A cell surface tethered enzyme improves efficiency in gene-directed enzyme prodrug therapy. Nat Biotechnol. 1997;15:1373-1377.
31. Stabila PF, Wong SC, Kaplan FA, et al. Cell surface expression of a human IgG Fc chimera activates macrophages through Fc receptors. Nat Biotechnol. 1998;16:1357-1360.
32. Gruel N, Fridman WH, Teillaud JL. Bypassing tumor-specific and bispecific antibodies: triggering of antitumor immunity by expression of anti-Fc gammaR scFv on cancer cell surface. Gene Therapy. 2001;8:1721-1728.
33. Blochberger TC, Sabatine JM, Lee YC, et al. O-linked glycosylation of rat renal gamma-glutamyltranspeptidase adjacent to its membrane anchor domain. J Biol Chem. 1989;264:20718-20722.
34. Arribas J, Coodly L, Vollmer P, et al. Diverse cell surface protein ectodomains are shed by a system sensitive to metalloprotease inhibitors. J Biol Chem. 1996;271:11376-11382.
35. Mullberg J, Rauch CT, Wolfson MF, et al. Further evidence for a common mechanism for shedding of cell surface proteins. FEBS Lett. 1997;401:235-238.
36. Kajita M, Itoh Y, Chiba T, et al. Membrane-type 1 matrix metalloproteinase cleaves CD44 and promotes cell migration. J Cell Biol. 2001;153:893-904.
37. Wedrychowski A, Kim YW, Chang TW. Immune enhancers composed of polyvalent binding sites of anti-CD3 antibodies. Biotechnology (NY). 1993;11:486-489.
38. Hirsch R, Bluestone JA, DeNenno L, et al. Anti-CD3 F(ab′)2 fragments are immunosuppressive in vivo without evoking either the strong humoral response or morbidity associated with whole mAb. Transplantation. 1990;49:1117-1123.
39. Vossen AC, Tibbe GJ, Kroos MJ, et al. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppression, but triggers cytokine-related side effects. Eur J Immunol. 1995;25:1492-1496.
40. Anton van der Merwe P, Davis SJ, Shaw AS, et al. Cytoskeletal polarization and redistribution of cell-surface molecules during T cell antigen recognition. Semin Immunol. 2000;12:5-21.
41. van der Merwe PA. The TCR triggering puzzle. Immunity. 2001;14:665-668.
42. Seliger B, Cabrera T, Garrido F, et al. HLA class I antigen abnormalities and immune escape by malignant cells. Semin Cancer Biol. 2002;12:3-13.
43. Ochsenbein AF, Sierro S, Odermatt B, et al. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 2001;411:1058-1064.
44. Brentjens RJ, Latouche JB, Santos E, et al. Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15. Nat Med. 2003;9:279-286.
45. Surman DR, Dudley ME, Overwijk WW, et al. Cutting edge: CD4+ T cell control of CD8+ T cell reactivity to a model tumor antigen. J Immunol. 2000;164:562-565.
46. Bowman L, Grossmann M, Rill D, et al. IL-2 adenovector-transduced autologous tumor cells induce antitumor immune responses in patients with neuroblastoma. Blood. 1998;92:1941-1949.
47. Schneeberger A, Koszik F, Schmidt W, et al. The tumorigenicity of IL-2 gene-transfected murine M-3D melanoma cells is determined by the magnitude and quality of the host defense reaction: NK cells play a major role. J Immunol. 1999;162:6650-6657.
48. Schoenberger SP, Toes RE, van der Voort EI, et al. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393:480-483.
49. Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393:474-478.
50. Bourgeois C, Rocha B, Tanchot C. A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory. Science. 2002;297:2060-2063.
51. Huang AY, Golumbek P, Ahmadzadeh M, et al. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science. 1994;264:961-965.
52. Bai XF, Gao JX, Liu J, et al. On the site and mode of antigen presentation for the initiation of clonal expansion of CD8 T cells specific for a natural tumor antigen. Cancer Res. 2001;61:6860-6867.
53. thor Straten P, Becker JC, Guldberg P, et al. In situ T cells in melanoma. Cancer Immunol Immunother. 1999;48:386-395.
54. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
55. Bloom MB, Perry-Lalley D, Robbins PF, et al. Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med. 1997;185:453-459.
56. Perricone MA, Claussen KA, Smith KA, et al. Immunogene therapy for murine melanoma using recombinant adenoviral vectors expressing melanoma-associated antigens. Mol Ther. 2000;1:275-284.
57. Seliger B, Wollscheid U, Momburg F, et al. Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. Cancer Res. 2001;61:1095-1099.